Literature DB >> 23404538

Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells.

Xiaozhi Liu1, Gang Li, Zhiguo Su, Zhongmin Jiang, Lei Chen, Junfei Wang, Shizhu Yu, Zhenlin Liu.   

Abstract

microRNAs are regarded as promising drugs for glioma gene therapy. However, conventional administration routes, such as oral administration and intravenous infusion, present low efficiency due to the blood-brain barrier and intercellular retention, thereby limiting their application. Recent studies showed poly(amido amine) (PAMAM) was a candidate carrier due to its high solubilization, delayed release and low toxicity. In the present study, U251 human brain glioma cells were transfected with the miR-7 gene using PAMAM as the vector to determine the transfection efficiency and therapeutic effects in vivo and in vitro. We found that PAMAM exhibited higher transfection efficiency and longer duration of action compared with liposome delivery, and miR-7 efficiently silenced some genes involved in the epidermal growth factor receptor (EGFR) pathway and achieved favorable effects in treating glioma in vivo and in vitro. These investigations provide a basis for developing high-efficiency micromolecular drug delivery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404538     DOI: 10.3892/or.2013.2283

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  MiR-302c-3p suppresses invasion and proliferation of glioma cells via down-regulating metadherin (MTDH) expression.

Authors:  Yonghong Wang; Yujun Wei; Haibo Tong; Laizhao Chen; Yimin Fan; Yuchen Ji; Wenqing Jia; Dongkang Liu; Guihuai Wang
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 2.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

3.  Polymer nanocarriers for MicroRNA delivery.

Authors:  Chintan H Kapadia; Benjamin Luo; Megan N Dang; N'Dea Irvin-Choy; Danielle M Valcourt; Emily S Day
Journal:  J Appl Polym Sci       Date:  2019-11-12       Impact factor: 3.125

Review 4.  Nanoscale delivery systems for microRNAs in cancer therapy.

Authors:  Sanda Boca; Diana Gulei; Alina-Andreea Zimta; Anca Onaciu; Lorand Magdo; Adrian Bogdan Tigu; Calin Ionescu; Alexandru Irimie; Rares Buiga; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2019-10-21       Impact factor: 9.261

Review 5.  Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.

Authors:  Yogesh Sharma; Adesh K Saini; Sheetal Kashyap; Gourav Chandan; Narinder Kaur; Vijai Kumar Gupta; Vijay Kumar Thakur; Vipin Saini; Reena V Saini
Journal:  Immunol Res       Date:  2021-10-29       Impact factor: 2.829

Review 6.  Nanocarrier-based therapies for CNS tumors.

Authors:  Toral R Patel
Journal:  CNS Oncol       Date:  2014-03

Review 7.  MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.

Authors:  Michael Henriksen; Kasper Bendix Johnsen; Hjalte Holm Andersen; Linda Pilgaard; Meg Duroux
Journal:  Mol Neurobiol       Date:  2014-03-12       Impact factor: 5.590

Review 8.  Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection.

Authors:  Vrantika Chaudhary; Sumit Jangra; Neelam R Yadav
Journal:  J Nanobiotechnology       Date:  2018-04-13       Impact factor: 10.435

Review 9.  Potential Epigenetic-Based Therapeutic Targets for Glioma.

Authors:  Lanlan Zang; Shukkoor Muhammed Kondengaden; Fengyuan Che; Lijuan Wang; Xueyuan Heng
Journal:  Front Mol Neurosci       Date:  2018-11-15       Impact factor: 5.639

Review 10.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.